Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2013.531 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY | Dr Ozaki Risa |
| 2015.703 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2024.240 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | Prof. HUI David Shu Cheong |
| 2015.535 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection |
Prof. LEUNG Ting Fan 梁廷勳 |
| 2015.459 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma |
Prof. CHAN Lam 陳林 |
| 2016.606 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2018.151 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2009.223 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma | Professor Ma Brigette |
| 2020.309 | A Phase 2, Randomized, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging, Dose-finding, Parallel Group Study to Assess Efficacy and Safety of PF 06865571 (DGAT2i) Alone and When Coadministered with PF-05221304 (ACCi) in Adult Participants with Biopsy-confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3 | Dr. YIP Wai Man |
| 2020.303 | A Phase 2, Randomized, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging, Dose-finding, Parallel Group Study to Assess Efficacy and Safety of PF 06865571 (DGAT2i) Alone and When Coadministered with PF-05221304 (ACCi) in Adult Participants with Biopsy-confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3 |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2008.198 | A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | Prof. CHAN Anthony T.C. |
| 2012.200 | A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus | Prof. TAM Lai Shan |
| 2024.456 | A Phase 2, Open-Label, Single-Arm Study of Amivantamab and Lazertinib Combination Therapy as First-Line Treatment in Patients with EGFR-Mutated Recurrent Non-Small Cell Lung Cancer after Previous Treatment with Adjuvant Osimertinib in Early-Stage Disease | Dr. LI Molly Siu Ching |
| 2016.190 | A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected with Chronic Hepatitis B Virus |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2017.530 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2017.531 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment |
Dr. HUI Aric Josun 許祖紳醫生 |
| 2022.070 | A Phase 2, Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2008.399 | A Phase 2, Open Label, Trial of PF-00299804 in Selected Patients with Untreated Advanced Adenocarcinoma of the Lung | PROF. MOK TONY S.K. |
| 2009.594 | A Phase 2, Multicenter, Randomized Study of Two Different Dose Regimens of Eribulin Mesylate in Combination with Intermittent Erlotinib in Patients with Previously Treated, Advanced Non-Small Cell Lung Cancer | Prof. MOK Tony Shu Kam |
| 2007.230 | A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination with Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer | Prof. Mok S.K. Tony |
| 2014.482 | A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy | Prof. SZETO Cheuk Chun |
| 2010.336 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects with Liver Fibrosis due to Chronic Hepatitis B Infection | Prof. CHAN Henry Lik Yuen |
| 2010.530 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects with Liver Fibrosis due to Chronic Hepatitis B Infection | Dr. HUI Aric Josun |
| 2003.180 | A Phase 2, Double-Bind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of SCH 420814 as Monotherapy in Subjects with Early Parkinson's Disease | Prof. Wong Ka Sing Lawrence |
| 2007.420 | A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 5 mg BID | Prof. Mok C.T. Vincent |
| 2006.317 | A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of A Range of SCH 420814 Doses (1mg BID, 2mg BID, 5mg BID, and Possibly 10mg BID) in Subjects with Moderate to Severe Parkinson | Dr. Mok C.T. Vincent |
| 2021.556 | A phase 2 trial of TAS 102 in recurrent/metastatic nasopharyngeal carcinoma |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2021.316 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection | Dr. YIP Wai Man |
| 2021.297 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Conatining VIR-2218, VIR-3434, and/or PEG-IFNa in Subjects with Chronic Hepatitis B Virus Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2018.271 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects with IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy including Dense Deposit Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.179 | A Phase 2 Study of Oraxol in Subjects with Cutaneous Angiosarcoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2021.563 | A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer |
Prof. YEO Winnie 楊明明教授 |
| 2003.030 | A Phase 2 Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer | Prof. Yeo Winnie |
| 2009.308 | A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy | Dr. WONG Raymond Siu Ming |
| 2003.191 | A Phase 2 Study of Fenretinide In Patients with Hormone Refractory Prostate Cancer | Prof. Mok S.K. Tony |
| 2022.678 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in Participants with Chronic Hepatitis B Infection (STRIVE) | Prof. WONG Grace Lai Hung |
| 2022.676 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in HBeAg-negative Participants with Low Viral Burden of Chronic Hepatitis B Infection (THRIVE) | Prof. WONG Grace Lai Hung |
| 2022.634 | A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus |
Prof. LUK Andrea On Yan 陸安欣 |
| 2019.022 | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2024.174 | A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic Non–Small-Cell Lung Cancer (mNSCLC) | Dr. LI Molly Siu Ching |
| 2022.571 | A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-02: Patients With Disease Progression After Receiving Systemic Treatment for Non-Small-Cell Lung Cancer (NSCLC) |
Dr. LI Molly Siu Ching 李兆澄醫生 |
| 2022.182 | A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study |
Prof. NG Chi Fai 吳志輝 |
| 2021.112 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2021.113 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Dr. YIP Wai Man |
| 2023.268 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2022.285 | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) |
Prof. YEO Winnie 楊明明 |
| 2024.095 | A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors | Prof. MA Brigette Buig Yue |
| 2024.183 | A Phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression | Dr. LI Molly Siu Ching |
| 2009.595 | A Phase 1B/2 Study of SCH 900105 in Combination with Gefitinib in Asian Subjects with Non-Small Cell Lung Cancer | Professor Mok Tony |
| 2019.159 | A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
Page 238 of 254.